Wells Fargo analyst Stephen Baxter raised the firm’s price target on McKesson (MCK) to $641 from $535 and keeps an Equal Weight rating on the shares. The firm updated estimates and price targets for the drug distribution group following the results and recent mergers. It is “generally constructive” on core distribution fundamentals into 2025, but says valuations and overhangs leave it neutral across the group.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK: